A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
PHASE1CompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
March 10, 2023
Primary Completion Date
August 2, 2023
Study Completion Date
August 2, 2023
Conditions
Healthy
Interventions
DRUG
[¹⁴C]Enlicitide chloride
IV Injection
Trial Locations (1)
53704
Labcorp Clinical Research Unit Inc. (Site 0001), Madison
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT06658626 - A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016) | Biotech Hunter | Biotech Hunter